Philippe Willemsen's Biography

• Home
• |
• Register
• |
• Submissions
• |
• Agenda
• |
• Exhibition
• |
• Venue
• |
• Media
• |

Description of the Challenges and Opportunities Related to the Clinical Development and Commercialization of Allogeneic Stem Cells in Orphan Disease Market. Illustration with the Practical Case of the Belgian Cell Therapy Company Promethera Biosciences

Friday, 6 September 2013 at 09:00

Add to Calendar ▼2013-09-06 09:00:002013-09-06 10:00:00Europe/LondonDescription of the Challenges and Opportunities Related to the Clinical Development and Commercialization of Allogeneic Stem Cells in Orphan Disease Market. Illustration with the Practical Case of the Belgian Cell Therapy Company Promethera BiosciencesStem Cells and Cell Therapy Summit in London, UKLondon, UKSELECTBIOenquiries@selectbiosciences.com

Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using stem cells from healthy human livers.  Promethera® Biosciences develops a new cell therapy product using allogeneic stem cells expanded from healthy human liver tissue. This product called Promethera® HepaStem aims to treat a wide variety of liver genetic and acquired diseases affecting children and adults. The innovation resides in both the simplicity of the treatment, which doesn’t require radical surgery (compared to liver transplantation), and in the wide variety of liver pathologies that can be addressed with the same product. This product has received two orphan drug designations from the European Community and the FDA for the treatment of Crigler-Najjar syndrome and urea cycle disease. In conjunction, Promethera® Biosciences is developing, Promethera® HepaScreen, a unique cell model for the pharmaceutical industry to mimic metabolism and detoxification of new drugs by the human liver. Both products are based on newly discovered and patented stem cell types. Eric Halioua, CEO of Promethera Biosciences, will illustrate the opportunities and challenges in terms of commercialization for an allogeneic stem cell product.